The rationale for the preoperative therapy for cancer of the esophagus is described. The first trial with infusion FUra mitomycin-c and radiation performed at Wayne State University (WSU) is described. The dramatic responses were duplicated when cisplatin was substituted for mitomycin. Moreover, survival was improved over the mitomycin-c trial. These neoadjuvant trials led to a third WSU clinical trial in which the neoadjuvant therapy became the definitive therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF00178195 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!